Sandfly bites transmit the intracellular protozoan Leishmania to cause leishmaniasis that exhibits with clinical presentations ranging from a cutaneous ulcer to treatment-resistant lethal systemic disease (visceral leishmaniasis; VL). VL reportedly kills 20,000 to 30,000 every year according to the World Health Organization, where current medications are limited by side effects and evolving antibiotic resistance. Accordingly, there is a great need to develop alternatives.

Researchers from Anhui Medical University (AMU) presented data from a study that aimed to assess the role of gastrin-releasing peptide (GRP) and its receptor GRPR in acute kidney injury (AKI).

Researchers from Collaborations Pharmaceuticals Inc. recently reported the discovery and preclinical evaluation of a novel pleconaril-based molecule, 11526092, being develop as an antiviral agent against enteroviruses.

In a recent publication, researchers from Institute of Medicinal Biotechnology and affiliated organizations described a novel group of antitubercular agents with an improved safety profile.

Third Harmonic Bio Inc. has announced a new product candidate, THB-335, a potent, highly selective, oral, small-molecule KIT inhibitor.

Transplanted human glial cells could outcompete human glia in a chimeric mouse model of Huntington’s disease, inducing apoptosis. And younger health cells could outcompete older ones. The findings, which appeared online in Nature Biotechnology on July 17, 2023, help pave the way for testing glial cell transplantation as a therapeutic strategy in neurodegenerative disorders.

The overexpression of the MYC oncogene could be explained through a new pathway that would act before transcription, when MYC binds to DNA. A group of scientists from Spain have identified how the ERK2 kinase interacted with the CDK9 protein, enabling it to bind to DNA in the promoter region of MYC.